v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Operating Expenses        
Research and development expenses $ 1,730,444 $ 1,688,164 $ 3,269,555 $ 3,342,509
General and administrative expenses 1,351,580 1,026,301 2,622,067 3,477,490
Operating Loss (3,082,024) (2,714,465) (5,891,622) (6,819,999)
Other Income (Expense), net 71,698 101,900 154,915 185,361
Net Operating Loss Before Income Tax Benefit (3,010,326) (2,612,565) (5,736,707) (6,634,638)
Income Tax Benefit
Net Loss $ (3,010,326) $ (2,612,565) $ (5,736,707) $ (6,634,638)
Net Loss per Common Share - Basic $ (1.01) $ (1.94) $ (2.11) $ (5.34)
Net Loss per Common Share - Diluted $ (1.01) $ (1.94) $ (2.11) $ (5.34)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic 2,983,283 1,346,808 2,724,903 1,243,475
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted 2,983,283 1,346,808 2,724,903 1,243,475

Source